Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-05-13
2008-05-13
Minnifield, Nita (Department: 1645)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S012200, C514S002600, C536S023100, C536S024100, C536S024330, C424S278100
Reexamination Certificate
active
07371734
ABSTRACT:
The present invention relates to 3′-OH, 5′-OH polynucleotide sequence compositions and methods for activating an immune response in an individual, and more preferably, for activating antigen presenting cells in the individual. In one embodiment, the antigen presenting cell is a dendritic cell. The present invention also includes compositions and methods for activating dendritic cells in vitro. These dendritic cells may then be administered to an individual. Preferred 3′-OH, 5′-OH polynucleotide sequences comprise six bases wherein at least 50% of the bases are guanine and the 5′ base is guanine. The compositions may comprise a phosphodiester or phosphorothioate backbone.
REFERENCES:
patent: 6239116 (2001-05-01), Krieg et al.
patent: 6339068 (2002-01-01), Krieg et al.
patent: 6809081 (2004-10-01), Phillips et al.
patent: 6821957 (2004-11-01), Krieg et al.
patent: 7087586 (2006-08-01), Filion et al.
patent: 7157436 (2007-01-01), Phillips et al.
patent: 2003/0125290 (2003-07-01), Phillips et al.
patent: 2003/0212026 (2003-11-01), Krieg et al.
patent: 2004/0009949 (2004-01-01), Krieg
patent: 2004/0067902 (2004-04-01), Bratzler et al.
patent: 2004/0186067 (2004-09-01), Krieg et al.
patent: 2004/0235774 (2004-11-01), Bratzler et al.
patent: 2005/0032734 (2005-02-01), Krieg et al.
patent: 2006/0154890 (2006-07-01), Bratzler et al.
patent: 2006/0182793 (2006-08-01), Bachmann et al.
patent: 2006/0211639 (2006-09-01), Bratzler et al.
patent: 2006/0287263 (2006-12-01), Davis et al.
patent: 2007/0066554 (2007-03-01), Krieg et al.
patent: 2007/0184068 (2007-08-01), Renner et al.
patent: WO 99/58118 (1999-11-01), None
patent: WO 99/65924 (1999-12-01), None
patent: WO 00/14217 (2000-03-01), None
patent: WO 01/07055 (2001-02-01), None
patent: WO 01/22990 (2001-04-01), None
patent: WO 01/44465 (2001-06-01), None
patent: WO 01/68117 (2001-09-01), None
patent: WO 03/024481 (2003-03-01), None
patent: WO 03/028764 (2003-04-01), None
Wloch et al, Human Gene Therapy, 1998, 9:1439-1447.
Lipford et al, Immunology, 2000, 101:46-52.
Filion et al, Vaccine, 2004, 22:2480-2488.
Harandi et al, J. Virology, 2003, 77/2:953-962.
Klimuk et al, J. Invest. Dermatol., 2004, 122:1042-1049.
Hartmann et al, Eur. J. Immunol., 2003, 33:1633-1641.
Ballas et al, J. Immunology, 2001, 167:4878-4886.
Jugde et al, Human Immunology, 2004, 65:218-230.
Kwant et al, Vaccine, 2004, 22:3098-3104.
Filion et al, Vaccine, 2003, 21:983-989.
Dalpke et al, Immunology, 2002, 106:102-112.
Filion et al, Expert Opinion Invest. Drugs, 2001, 10/12:2157-2165.
Shen et al, Antisense and Nucleic Acid Drug Development, 2002, 12:155-164.
Shen et al, FASEB Journal, 2001 15/5:A1199 abstract #946.12 FASEB Meeting of Mar. 2001.
Shimosato et al, Animal Science Journal, 2004, 75:377-382.
Levtin, New England J. Medicine, 1993, 329/19:1400-1405.
Haynes, Science, 1993, 260:1279-1286.
Bystryn, Cancer and Metastasis Reviews, 1990, 9:81-91.
Kurtis et al, Trends inParasitology, 2001, 17/5:219-223.
Arevalo-Herrera et al, Molecular Immunology, 2001, 38:443-455.
Satoh et al, Fukushima Igaku Zasshi, 2002, 52/3:237-250.
Dziadzio et al, Handbook of Experimental Pharmacology, 2004, 161(Pharmacology and Therapeutics of ASthma and COPD):273-285.
McCluskie et al, Molecular Medicine, 1999, 5/5:287-300.
Agrawal et al, Molecular Medicine Today, 2000, 6:72-81.
Wohlleben et al, Trends in Immunology, Nov. 2001, 22/11:618-626.
Krieg et al, Immunology Today, Oct. 2000, 21/10:521-526.
Kline et al, Am. J. Physiol. Lung Cell Mol. Physiol., 2002, 283:L170-L179.
Kline et al, J. Immunology, 1998, 160:2555-2559.
Donnelly, Nature Medicine, Nov. 2003m 9/11:1354-1356.
de Gruijl et al, Nature Medicine, Oct. 1999, 5/10:1124-1125.
Weiner, J. Leukoc. Biol., 2000, 68:455-463.
Bitton, Current Opinion in Molecular Therapeutics, 2004, 6/1:17/26.
Agrawal et al, Trends in Molecular Medicine, Mar. 2003, 8/3:114-121.
Mempel et al, Immunology Letters, 2003, 89:47-57.
Shen et al, J. Autoimmunity, 2005, 24:183-190.
Holmgren et al, immunology Letters, 2005, 97:181-188.
Krieg et al, Pharamcology and Therapeutics, 1999, 84:113-120.
Senuma et al, Cytokine, Oct. 2002, 20/1:23-29.
Staines, Medical Hypotheses, 2005, Article in Press, 5 pp.
Garg et al, J. Autoimmunity, 1999, 11:371-378.
Mocellin et al, Lancet Oncology, Dec. 2004, 5/12:727-737, abstract only.
Hegmans et al, Am. J. Respir. Crti. Care Med., May 2005, 171/10:1168-1177 abstract only.
Kao et al, Immunology Letters, Jun. 30, 2005, abstract only.
Alexander et al, Cancer Immunol. Immunother., Jun. 18, 2005, abstract only.
Foon et al, J. Clin. Oncol., Sep. 1999, 17/9:2889-2895 abstract only.
Ridgway, Cancer Invest., 2003, 21/6:873-886.
Ciurli et al, Clinical & Investigative Medicine, Aug. 2004, 27/4: Poster #29, Abstract only.
Ciurli et al, Clinical & Investigative Medicine, Aug. 2004, 27/4: Poster #30 abstract only.
Phillips et al, Cancer Detection and Prevention, 1990, 14/4:491-496.
Phillips et al, Cancer Detection and Prevention, 1988, 12:451-459.
Lang et al, Eur. J. Immunol. 1999, 29:3496-3506.
Bates et al, JBC, 274/37:26369-26377.
Goutteangeas et al, Nature Biotechnology, May 2000, 18:491-492.
Bodey et al, Anticancer Research, 2000, 20:2665-2676.
Trichopoulos et al, Scientific American, “What Causes Cancer?” Sep. 1996, 14 pages.
Weinberg, Scientific American, “How Cancer Arises”, Sep. 1996, 14 pages.
Old, Scientific American, “Immunotherpay for Cancer”, Sep. 1996, 12 pages.
Saleh et al, Current Pharmaceutical Design, 2005, 11:3461-3473.
Lee, et al.,J. of Immunology, vol. 165, pp. 3631-3639, 2000.
Krieg, “CpG Motifs in Bacterial DNA and Their Immune Effects”,Annu. Rev. Immunol., 2002, 20:709-760.
Sparwasser et al., “Bacterial DNA and Immunostimulatory CpG Oligonucleotides Trigger Maturation and Activation of Murine Dendritic Cells”,Eur. J. Immunol, 1998, 28:2045-2054.
Hartman et al., “CpG DNA: A Potent Signal for Growth, Activation, and Maturation of Human Dendritic Cells”,Proc. Natl. Acad. Sci. USA, 1999, 96:9305-9310.
Askew et al., “CpG DNA Induces Maturation of Dendritic Cells with Distinct Effects on Nascent and Recycling MHC-II Antigen-Processing Mechanisms”,J. Immunol., 2000, 165(12) 6889-6895, Dec. 2000.
Kadowaski et al., “Distinct CpG DNA and Polyinosinic-Polycytidylic Acid Double-Stranded RNA, Respectively, Stimulate CD11c-Type 2 Dendritic Cell Precursors and CD11c+ Dendritic Cells to Produce Type 1 IFN1”J. Immunol., 2001, 166 (4):2291-2295.
Filion Mario C.
Phillips Nigel C.
Bioniche Life Sciences Inc.
Kilpatrick & Stockton LLP
Minnifield Nita
LandOfFree
Oligonucleotide compositions and their use for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleotide compositions and their use for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotide compositions and their use for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2805436